Ciprofloxacin plus vancomycin versus ceftazidime plus gentamicin in the treatment of pneumonia in granulocytopenic patients with or without venous catheters. Short communication.
58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.) + vancomycin (VAN; 0.5-1 g, i.v. b.i.d.), and group 2, which included patients without venous catheters treated with ceftazidime (2 g, i.v. t.i.d.) + gentamicin (1 mg/kg, i.v. t.i.d.). Pneumonia was diagnosed clinically and radiologically in all patients; 92.3% in group 1 and 46.8% in group 2 were also microbially confirmed. Mixed infections were present in most patients. 3 of 26 patients (11.5%) in group 1 and 9 of 32 (20.1%) in group 2 did not recover while 88.5% in group 1 and 71.9% in group 2 recovered. CIP + VAN seems to be more effective in treating pneumonia in neutropenic patients, with only 1 patient in the group suffering an adverse effect compared with 5 in group 2.
Krcméry
V
V
Department of Clinical Oncology, Postgraduate Medical School, Bratislava, CSFR.
Fuchsberger
P
P
Trupl
J
J
Sufliarsky
J
J
Spanik
S
S
Koza
I
I
Kusenda
Z
Z
Korec
S
S
Svec
J
J
Durkovic
P
P
D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D001996:Bronchopneumonia / Q000188:drug therapy*; D002404:Catheterization; D002442:Ceftazidime / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D014640:Vancomycin / Q000627:therapeutic use
D005839:Gentamicins; D002939:Ciprofloxacin; D014640:Vancomycin; D002442:Ceftazidime